Brenner Sabando V.
@BrennerSabando
Followers
92
Following
8
Media
8
Statuses
72
Médico Hematólogo IRHED (Instituto de Reumatología, hematología y Dermatología) Hospital Luis Vernaza Universidad UEES
IRHED
Joined March 2017
A State of the Art Review of Myeloproliferative Neoplasms in Adolescent and Young Adult Population led by @HannahGoulart and @doctorpemm of @MDAndersonNews #MPNSM #AYASM #endcancer
https://t.co/z5hvXjniTF
@mpdrc
@harrisoncn1
@MDmasarova
@jjkiladjian
1
26
67
CONGRESS | #EHA2024 In the plenary abstracts session, Uwe Platzbecker @UwePlatzbecker @UniLeipzig presents the first results from the open-label randomized phase III APOLLO trial of ATO with ATRA and Ida vs standard ATRA plus chemotherapy regimen in 131 patients with ND HR #APL.
2
31
81
New therapeutic approaches are needed for relapse/refractory acute lymphoblastic leukemia (ALL). Read here the new review on available antibodies for the treatment of childhood ALL. https://t.co/ON64q5Yrrc
0
48
138
Interesantes resultados, que puede cambiar nuestra conducta terapéutica.
CONGRESS #EHA2024 | Peter Borchmann #cioabcd presents the final analysis of phase III #HD21 trial of PET2-individualized BrECADD regimen vs intensified BEACOPP in patients with advanced-stage #HodgkinLymphoma. BrECADD had superior efficacy (PFS 94.3% vs 90.9% at 4 yr) with
0
0
0
CONGRESS #EHA2024 | Philippe Moreau, @CHUnantes presents long-term outcomes from the phase III CASSIOPEIA trial of D-VTd followed by DARA maintenance in transplant-eligible patients with NDMM. D-VTd induction and consolidation plus DARA maintenance resulted in the most pronounced
2
24
61
How I treat the co-occurrence of venous and arterial thromboembolism: anticoagulation, antiplatelet therapy, or both? https://t.co/mfPMFth7We
#HowITreat #thrombosisandhemostasis
0
49
133
Interesantes resultados … rumbo al cambio de estándar para Linfoma de Hodgkin avanzado
CONGRESS #ASCO24 | Peter Borchmann, MD #cioabcd presented the first report of the final analysis of phase III #HD21 trial of PET2-individualized BrECADD regimen vs intensified BEACOPP in patients with advanced-stage #HodgkinLymphoma. BrECADD had superior efficacy (PFS 94.3% vs
0
0
0
CONGRESS | #ASCO24 | @paurotero @ClinicaNavarra presents an analysis of MRD from the PERSEUS trial of D-VRd vs VRd in transplant-eligible NDMM. D-VRd vs VRd, 48-mo PFS 84.3% vs 67.7%, sustained MRDneg x10-5 64.8% vs 29.7%, overall MRDneg x10-6 65.1% vs 32.2%, there was a 58%
3
18
29
Bleeding Risks in Patients With MPNs Increased With Anticoagulant Use, Antiplatelet Therapy https://t.co/16gAgOpLce Prudencia ... los sangrados también complican
0
0
0
Characterizing Long-Term Outcomes of Eltrombopag in Patients With Severe Aplastic Anemia https://t.co/Zod89gbCoY Creo eltrombopag es especialmente útil en los pacientes mayores no aptos a inmunosupresión con timoglobulina
0
1
3
USPSTF Report: Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality https://t.co/oeLN0DPsVH a través de @JAMA_current part of @JAMANetwork
0
0
0
Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis: Annals of Internal Medicine: Vol 0, No 0 https://t.co/v9F3NZK3gP Siempre es importante ver pro y contras en decisión
0
1
1
Second-Line Pembrolizumab Plus GVD in Relapsed/Refractory Classical Hodgkin Lymphoma https://t.co/H7IUyZGOEm Muy interesante y sin precedente...95% de respuesta completa en pacientes con LInfoma de Hodgkin clásico refractarios/recaidos.
ashclinicalnews.org
Second-Line Pembrolizumab Plus GVD in Relapsed/Refractory Classical Hodgkin Lymphoma - Literature Scan, Lymphomas & Lymphoid Neoplasia, News - ASH Clinical News
0
0
1
Corticosteroid-Dependent or Corticosteroid-Unresponsive Primary ITP
ashclinicalnews.org
Corticosteroid-Dependent or Corticosteroid-Unresponsive Primary ITP - Bleeding Disorders, Education, How I Treat In Brief - ASH Clinical News
0
0
1
Limitations of randomized controlled trials - By Maxime Beydon @BeydonMaxime (fellow in Internal Medicine, Paris, France) #RCT #InternistAcademy 2021
2
11
23
Coffee Consumption and Incident Tachyarrhythmias https://t.co/kiNto68hBB a través de @JAMAInternalMed part of @JAMANetwork Ahora tendré que seguir disfrutando de un delicioso café Ecuatoriano...
jamanetwork.com
This cohort study assesses the association between consumption of common caffeinated products and the risk of arrhythmias using data from the UK Biobank.
0
0
0
How I assess and manage the risk of bleeding in patients treated for venous #thromboembolism
https://t.co/VXaZVBoJ52
@BloodJournal #VTE
0
22
24